See more : Zhejiang Taimei Med Tech Co (2576.HK) Income Statement Analysis – Financial Results
Complete financial analysis of ShockWave Medical, Inc. (SWAV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ShockWave Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Zhejiang Sunriver Culture Co.,Ltd. (600576.SS) Income Statement Analysis – Financial Results
- Innocean Worldwide Inc. (214320.KS) Income Statement Analysis – Financial Results
- A.Plus Group Holdings Limited (1841.HK) Income Statement Analysis – Financial Results
- Air China Limited (AIRYY) Income Statement Analysis – Financial Results
- Avanti Acquisition Corp. Redeem (AVAN-WT) Income Statement Analysis – Financial Results
ShockWave Medical, Inc. (SWAV)
About ShockWave Medical, Inc.
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 730.23M | 489.73M | 237.15M | 67.79M | 42.93M | 12.26M | 1.72M |
| Cost of Revenue | 95.39M | 65.00M | 41.44M | 20.99M | 17.16M | 7.25M | 2.84M |
| Gross Profit | 634.84M | 424.74M | 195.71M | 46.80M | 25.77M | 5.01M | -1.12M |
| Gross Profit Ratio | 86.94% | 86.73% | 82.53% | 69.03% | 60.03% | 40.88% | -64.98% |
| Research & Development | 145.65M | 81.68M | 50.54M | 36.93M | 32.85M | 22.70M | 17.96M |
| General & Administrative | 95.27M | 56.93M | 34.75M | 23.86M | 14.13M | 5.98M | 5.42M |
| Selling & Marketing | 234.84M | 162.00M | 111.29M | 51.67M | 30.62M | 17.54M | 6.36M |
| SG&A | 323.20M | 218.92M | 146.04M | 75.54M | 44.75M | 23.52M | 11.79M |
| Other Expenses | 23.96M | 1.06M | -582.00K | 1.26M | 2.35M | 589.00K | 366.00K |
| Operating Expenses | 468.85M | 300.60M | 196.58M | 112.46M | 77.61M | 46.21M | 29.75M |
| Cost & Expenses | 564.24M | 365.60M | 238.02M | 133.45M | 94.77M | 53.46M | 32.58M |
| Interest Income | 0.00 | 1.89M | 1.10M | 1.21M | 944.00K | 0.00 | 0.00 |
| Interest Expense | 6.20M | 1.89M | 1.10M | 1.21M | 944.00K | 401.00K | 58.00K |
| Depreciation & Amortization | 10.36M | -1.42M | -6.87M | 1.26M | 2.35M | 700.00K | 468.00K |
| EBITDA | 176.35M | 127.57M | -871.00K | -62.32M | -49.56M | -39.91M | -30.03M |
| EBITDA Ratio | 24.15% | 25.06% | -3.26% | -95.01% | -115.30% | -325.46% | -1,747.00% |
| Operating Income | 165.99M | 124.13M | -871.00K | -65.66M | -51.84M | -41.20M | -30.87M |
| Operating Income Ratio | 22.73% | 25.35% | -0.37% | -96.86% | -120.76% | -335.97% | -1,795.52% |
| Total Other Income/Expenses | 8.29M | -3.31M | -7.96M | 44.00K | 792.00K | 136.00K | 276.00K |
| Income Before Tax | 174.28M | 120.83M | -8.84M | -65.62M | -51.05M | -41.06M | -30.59M |
| Income Before Tax Ratio | 23.87% | 24.67% | -3.73% | -96.80% | -118.92% | -334.86% | -1,779.46% |
| Income Tax Expense | 27.00M | -95.17M | 301.00K | 80.00K | 62.00K | 38.00K | 26.00K |
| Net Income | 147.28M | 216.00M | -9.14M | -65.70M | -51.11M | -41.10M | -30.62M |
| Net Income Ratio | 20.17% | 44.10% | -3.85% | -96.92% | -119.06% | -335.17% | -1,780.98% |
| EPS | 4.01 | 6.02 | -0.26 | -1.99 | -2.14 | -1.53 | -1.57 |
| EPS Diluted | 3.85 | 5.70 | -0.26 | -1.99 | -2.14 | -1.53 | -1.57 |
| Weighted Avg Shares Out | 36.71M | 35.90M | 35.10M | 33.09M | 23.90M | 26.91M | 19.53M |
| Weighted Avg Shares Out (Dil) | 38.21M | 37.88M | 35.10M | 33.09M | 23.90M | 26.91M | 19.53M |
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Shockwave Medical (SWAV) Advances While Market Declines: Some Information for Investors
Shockwave Medical (SWAV) concluded the recent trading session at $329, signifying a +0.45% move from its prior day's close.
Why Shockwave Medical (SWAV) Could Beat Earnings Estimates Again
Shockwave Medical (SWAV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top 5 Non-Tech Nasdaq Winners of Q1 With More Upside Left
We have narrowed our search to five high-flying Nasdaq Composite listed non-tech stocks with more upside left. These are: CELH, SWAV, COIN, HOOD, IBKR.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, INRD
NEW YORK , April 9, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Shockwave Medical,...
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Shockwave Medical, Inc. - SWAV
NEW YORK , April 9, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
Shockwave Medical's (SWAV) Reducer Receives Positive Results
Shockwave Medical (SWAV) announces the 'real-world' results of the REDUCER-I study, which is intended to collect long-term outcomes on Shockwave Reducer, a novel treatment for refractory angina.
SHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAV
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Shockwave Medical, Inc. (NasdaqGS: SWAV) to Johnson & Johnson (NYSE: JNJ)....
Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World' Study
Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
On April 5, 2024, Johnson & Johnson NYSE: JNJ announced its intent to acquire Shockwave Medical Inc. NASDAQ: SWAV for $13.1 billion. Under the terms of the proposed deal, JNJ will pay $335 per share, which is a 4.75% premium...
Source: https://incomestatements.info
Category: Stock Reports